{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:43:19Z","timestamp":1791045799675,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>hbdPRELP is a peptide corresponding to the N-terminal heparin binding domain of the matrix protein proline\/arginine-rich end leucine-rich repeat protein (PRELP). hbdPRELP inhibits osteoclastogenesis entering pre-fusion osteoclasts through a chondroitin sulfate\u2013 and annexin 2\u2013dependent mechanism and reducing the nuclear factor-\u03baB transcription factor activity. In this work, we hypothesized that hbdPRELP could have a pharmacological relevance, counteracting bone loss in a variety of in vivo models of bone diseases induced by exacerbated osteoclast activity. In healthy mice, we demonstrated that the peptide targeted the bone and increased trabecular bone mass over basal level. In mice treated with retinoic acid to induce an acute increase of osteoclast formation, the peptide consistently antagonized osteoclastogenesis and prevented the increase of the serum levels of the osteoclast-specific marker tartrate-resistant acid phosphatase. In ovariectomized mice, in which osteoclast activity was chronically enhanced by estrogen deficiency, hbdPRELP counteracted exacerbated osteoclast activity and bone loss. In mice carrying osteolytic bone metastases, in which osteoclastogenesis and bone resorption were enhanced by tumor cell\u2013derived factors, hbdPRELP reduced the incidence of osteolytic lesions, both preventively and curatively, with mechanisms involving impaired tumor cell homing to bone and tumor growth in the bone microenvironment. Interestingly, in tumor-bearing mice, hbdPRELP also inhibited breast tumor growth in orthotopic sites and development of metastatic disease in visceral organs, reducing cachexia and improving survival especially when administered preventively. hbdPRELP was retained in the tumor tissue and appeared to affect tumor growth by interacting with the microenvironment rather than by directly affecting the tumor cells. Because safety studies and high-dose treatments revealed no adverse effects, hbdPRELP could be employed as a novel biological agent to combat experimentally induced bone loss and breast cancer metastases, with a potential translational impact.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.1951","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T14:27:41Z","timestamp":1365085661000},"page":"1912-1924","source":"Crossref","is-referenced-by-count":28,"title":["Proline\/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss"],"prefix":"10.1093","volume":"28","author":[{"given":"Nadia","family":"Rucci","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical SciencesUniversity of L'AquilaL'AquilaItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Capulli","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical SciencesUniversity of L'AquilaL'AquilaItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ventura","sequence":"additional","affiliation":[{"name":"Department of PathologySan Salvatore HospitalL'AquilaItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Angelucci","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical SciencesUniversity of L'AquilaL'AquilaItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peruzzi","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children's Hospital\u201cIstituto di Ricovero e Cura a Carattere Scientifico\u201d (IRCCS)RomeItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viveka","family":"Tillgren","sequence":"additional","affiliation":[{"name":"Department of Clinical SciencesSection of Rheumatology, Lund UniversityLundSweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Muraca","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children's Hospital\u201cIstituto di Ricovero e Cura a Carattere Scientifico\u201d (IRCCS)RomeItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Heineg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Clinical SciencesSection of Rheumatology, Lund UniversityLundSweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Teti","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical SciencesUniversity of L'AquilaL'AquilaItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"issue":"43","key":"2024020318361948700_jbmr1951-bib-0001","doi-asserted-by":"crossref","first-page":"25639","DOI":"10.1074\/jbc.270.43.25639","article-title":"The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues","volume":"270","author":"Bengtsson","year":"1995","journal-title":"J Biol Chem."},{"key":"2024020318361948700_jbmr1951-bib-0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/0471221929.ch4","volume-title":"Connective tissue and its heritable disorders: molecular, genetic, and medical aspects","author":"Heineg\u00e5rd","year":"2002"},{"issue":"5","key":"2024020318361948700_jbmr1951-bib-0003","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1083\/jcb.200906014","article-title":"The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis","volume":"187","author":"Rucci","year":"2009","journal-title":"J Cell Biol."},{"issue":"52","key":"2024020318361948700_jbmr1951-bib-0004","doi-asserted-by":"crossref","first-page":"40695","DOI":"10.1074\/jbc.M007917200","article-title":"The amino-terminal part of PRELP binds to heparin and heparan sulfate","volume":"275","author":"Bengtsson","year":"2000","journal-title":"J Biol Chem."},{"key":"2024020318361948700_jbmr1951-bib-0005","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2741\/e543","article-title":"Bone cells and the mechanism of bone remodelling","volume":"4","author":"Del Fattore","year":"2012","journal-title":"Front Biosci (Elite Ed)."},{"issue":"1","key":"2024020318361948700_jbmr1951-bib-0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med."},{"key":"2024020318361948700_jbmr1951-bib-0007","doi-asserted-by":"crossref","first-page":"197454","DOI":"10.4061\/2011\/197454","article-title":"A systematic review of osteoporosis health beliefs in adult men and women","volume":"2011","author":"McLeod","year":"2011","journal-title":"J Osteoporos."},{"issue":"1","key":"2024020318361948700_jbmr1951-bib-0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-004-0086-0","article-title":"Bone disease in pediatric rheumatologic disorders","volume":"6","author":"Burnham","year":"2004","journal-title":"Curr Rheumatol Rep."},{"key":"2024020318361948700_jbmr1951-bib-0009","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2024020318361948700_jbmr1951-bib-0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: advancing treatment and prevention","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"2024020318361948700_jbmr1951-bib-0011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer."},{"issue":"27","key":"2024020318361948700_jbmr1951-bib-0012","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/138161210793563554","article-title":"Therapeutic approach of primary bone tumours by bisphosphonates","volume":"16","author":"Moriceau","year":"2010","journal-title":"Curr Pharm Des."},{"issue":"1","key":"2024020318361948700_jbmr1951-bib-0013","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dustan","year":"2007","journal-title":"Natl Clin Pract Oncol."},{"key":"2024020318361948700_jbmr1951-bib-0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","article-title":"The use of bisphosphonates in cancer treatment","volume":"1218","author":"Coleman","year":"2011","journal-title":"Ann NY Acad Sci."},{"issue":"8","key":"2024020318361948700_jbmr1951-bib-0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/86.8.628","article-title":"Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement","volume":"86","author":"Sekyi-Otu","year":"1994","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2024020318361948700_jbmr1951-bib-0016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jss.2012.04.069","article-title":"Early protective effect of total hypoxic preconditioning on rats against systemic injury from hemorrhagic shock and resuscitation","volume":"178","author":"Duan","year":"2012","journal-title":"J Surg Res."},{"issue":"11","key":"2024020318361948700_jbmr1951-bib-0017","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risk and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer."},{"issue":"18","key":"2024020318361948700_jbmr1951-bib-0018","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med."},{"issue":"5","key":"2024020318361948700_jbmr1951-bib-0019","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med."},{"issue":"5","key":"2024020318361948700_jbmr1951-bib-0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4158\/EP.13.5.513","article-title":"Consensus and controversy regarding osteoporosis in the pediatric population","volume":"13","author":"Bachrach","year":"2007","journal-title":"Endocr Pract."},{"issue":"28","key":"2024020318361948700_jbmr1951-bib-0021","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol."},{"key":"2024020318361948700_jbmr1951-bib-0022","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy","author":"Schwarz","year":"2007","journal-title":"Arthritis Res Ther."},{"issue":"9","key":"2024020318361948700_jbmr1951-bib-0023","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1345\/aph.1M102","article-title":"Denosumab in osteoporosis and oncology","volume":"43","author":"Burkiewicz","year":"2009","journal-title":"Ann Pharmacother."},{"issue":"6","key":"2024020318361948700_jbmr1951-bib-0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MED.0b013e3282f169b5","article-title":"Cancer treatment-induced bone loss","volume":"14","author":"Adler","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"17","key":"2024020318361948700_jbmr1951-bib-0025","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.1074\/jbc.M108285200","article-title":"The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor","volume":"277","author":"Bengtsson","year":"2002","journal-title":"J Biol Chem."},{"issue":"11","key":"2024020318361948700_jbmr1951-bib-0026","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.1074\/jbc.M111.291476","article-title":"PRELP protein inhibits the formation of the complement membrane attack complex","volume":"287","author":"Happonen","year":"2012","journal-title":"J Biol Chem."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1951","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/9\/1912\/56563771\/jbmr1951.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/9\/1912\/56563771\/jbmr1951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:49:25Z","timestamp":1710341365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/9\/1912-1924\/7598710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,4,4]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1951","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9,1]]},"published":{"date-parts":[[2013,4,4]]}}}